A critical evaluation of migraine trigger site deactivation surgery

Headache

Volumn 54, Issue 1, 2014, Pages 142-152

  Mathew, Paul G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

Author keywords

contact point headache; cranial neuralgia; migraine headache trigger site deactivation surgery; migraine surgery; occipital neuralgia; supraorbital neuralgia

Indexed keywords

BOTULINUM TOXIN A;

CLINICAL EVALUATION; CLINICAL PRACTICE; CONTACT POINT HEADACHE; COST BENEFIT ANALYSIS; CUTANEOUS HYPERSENSITIVITY; DRUG EFFECT; FACIAL NERVE INJURY; FOLLOW UP; HAIR LOSS; HUMAN; HYPERSENSITIVITY; MICROVASCULAR DECOMPRESSION; MIGRAINE; MIGRAINE TRIGGER SITE DEACTIVATION SURGERY; NECK INJURY; NERVE COMPRESSION; NEURALGIA; NOSE SEPTUM RECONSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PERIPHERAL NERVE COMPRESSION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; PREOPERATIVE CARE; PRIORITY JOURNAL; PRURITUS; REVIEW; SCREENING TEST; STIFF NECK; SURGICAL TECHNIQUE; THERAPY EFFECT; ULTRASOUND;

CONTACT POINT HEADACHE; CRANIAL NEURALGIA; MIGRAINE HEADACHE TRIGGER SITE DEACTIVATION SURGERY; MIGRAINE SURGERY; OCCIPITAL NEURALGIA; SUPRAORBITAL NEURALGIA;

CONTROLLED CLINICAL TRIALS AS TOPIC; DECOMPRESSION, SURGICAL; HUMANS; MIGRAINE DISORDERS; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 84892372077     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12218     Document Type: Review

References (32)

1. Lipton RB, Stewart WF, Simon D,. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998; 38: 87-96.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M,. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-657.
3. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF,. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001; 41: 638-645.
4. Mathew PG, Garza I,. Headache. Semin Neurol. 2011; 31: 5-17.
5. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: Results from the second International Burden of Migraine Study (IBMS-II). Headache. 2013; 53: 644-655.
6. Guyuron B, Kriegler JS, Davis J, Amini SB,. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2011; 127: 603-608.
7. Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S,. A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg. 2009; 124: 461-468.
8. Oturai AB, Jensen K, Eriksen J, Madsen F,. Neurosurgery for trigeminal neuralgia: Comparison of alcohol block, neurectomy, and radiofrequency coagulation. Clin J Pain. 1996; 12: 311-315.
9. Taha JM, Tew JM Jr,. Comparison of surgical treatments for trigeminal neuralgia: Reevaluation of radiofrequency rhizotomy. Neurosurgery. 1996; 38: 865-871.
10. Robertson CE, Garza I,. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat. 2012; 8: 35-48.
11. Rosales RL, Bigalke H, Dressler D,. Pharmacology of botulinum toxin: Differences between type A preparations. Eur J Neurol. 2006; 13 (Suppl. 1): 2-10.
12. Mense S,. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004; 251 (Suppl. 1): I1-I7.
13. Arezzo JC,. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002; 18 (6 Suppl.): S125-S132.
14. Aoki KR,. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26: 785-793.
15. Pavone F, Luvisetto S,. Botulinum neurotoxin for pain management: Insights from animal models. Toxins. 2010; 2: 2890-2913.
16. Liu MT, Armijo BS, Guyuron B,. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg. 2012; 129: 413-419.
17. Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-814.
18. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM,; BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study. Headache. 2007; 47: 486-499.
19. Young W, Cook B, Malik S, Shaw J, Oshinsky M,. The first 5 minutes after greater occipital nerve block. Headache. 2008; 48: 1126-1128.
20. Weibelt S, Andress-Rothrock D, King W, Rothrock J,. Suboccipital nerve blocks for suppression of chronic migraine: Safety, efficacy, and predictors of outcome. Headache. 2010; 50: 1041-1044.
21. Rozen TD,. Intranasal contact point headache: Missing the "point" on brain MRI. Neurology. 2009; 72: 1107.
22. Mohebbi A, Memari F, Mohebbi S,. Endonasal endoscopic management of contact point headache and diagnostic criteria. Headache. 2010; 50: 242-248.
23. Leal PR, Hermier M, Souza MA, Cristino-Filho G, Froment JC, Sindou M,. Visualization of vascular compression of the trigeminal nerve with high-resolution 3T MRI: A prospective study comparing preoperative imaging analysis to surgical findings in 40 consecutive patients who underwent microvascular decompression for trigeminal neuralgia. Neurosurgery. 2011; 69: 15-26.
24. Tijssen C, Schoemaker K, Visser L,. Supraorbital neuralgia caused by nerve entrapment visualized on ultrasonography. Headache. 2013; 53: 376-377.
25. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
26. Alecrim-Andrade J, Maciel-Júnior JA, Cladellas XC, Correa-Filho HR, Machado HC,. Acupuncture in migraine prophylaxis: A randomized sham-controlled trial. Cephalalgia. 2006; 26: 520-529.
27. Leao AAP,. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944; 8: 379-390.
28. Milner P,. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. EEG Clin Neurophysiol. 1958; 10: 705.
29. Moskowitz MA, Nozaki K, Kraig RP,. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci. 1993; 13: 1167-1177.
30. Faber C, Garcia RM, Davis J, Guyuron B,. A socioeconomic analysis of surgical treatment of migraine headaches. Plast Reconstr Surg. 2012; 129: 871-877.
31. Harrison L, Jones NS,. Intranasal contact points as a cause of facial pain or headache: A systematic review. Clin Otolaryngol. 2013; 38: 8-22.
32. Caminero AB, Pareja JA,. Supraorbital neuralgia: A clinical study. Cephalalgia. 2001; 21: 216-223.